| Subjective and hormonal effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans DS Harris, M Baggott, JH Mendelson, JE Mendelson, RT Jones Psychopharmacology 162, 396-405, 2002 | 289 | 2002 |
| Plasma testosterone levels in heroin addiction and during methadone maintenance. JH Mendelson, JE Mendelson, VD Patch Journal of Pharmacology and Experimental Therapeutics 192 (1), 211-217, 1975 | 221 | 1975 |
| Bioavailability of sublingual buprenorphine J Mendelson, RA Upton, ET Everhart, PJ III, RT Jones The Journal of Clinical Pharmacology 37 (1), 31-37, 1997 | 217 | 1997 |
| The pharmacology of cocaethylene in humans following cocaine and ethanol administration DS Harris, ET Everhart, J Mendelson, RT Jones Drug and alcohol dependence 72 (2), 169-182, 2003 | 201 | 2003 |
| Cardiovascular effects of 3, 4-methylenedioxymethamphetamine: a double-blind, placebo-controlled trial SJ Lester, M Baggott, S Welm, NB Schiller, RT Jones, E Foster, ... Annals of Internal Medicine 133 (12), 969-973, 2000 | 173 | 2000 |
| Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations RP Nath, RA Upton, ET Everhart, P Cheung, P Shwonek, RT Jones, ... The Journal of Clinical Pharmacology 39 (6), 619-623, 1999 | 173 | 1999 |
| Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine DS Harris, RT Jones, S Welm, RA Upton, E Lin, J Mendelson Drug and alcohol dependence 61 (1), 85-94, 2000 | 171 | 2000 |
| Human pharmacology of the methamphetamine stereoisomers J Mendelson, N Uemura, D Harris, RP Nath, E Fernandez, P Jacob III, ... Clinical Pharmacology & Therapeutics 80 (4), 403-420, 2006 | 169 | 2006 |
| Buprenorphine and naloxone interactions in opiate‐dependent volunteers J Mendelson, RT Jones, I Fernandez, S Welm, AK Melby, MJ Baggott Clinical Pharmacology & Therapeutics 60 (1), 105-114, 1996 | 167 | 1996 |
| Methamphetamine and ethanol interactions in humans J Mendelson, RT Jones, R Upton, P Jacob III Clinical Pharmacology & Therapeutics 57 (5), 559-568, 1995 | 166 | 1995 |
| The bioavailability of intranasal and smoked methamphetamine DS Harris, H Boxenbaum, ET Everhart, G Sequeira, JE Mendelson, ... Clinical pharmacology & therapeutics 74 (5), 475-486, 2003 | 159 | 2003 |
| Chemical analysis of ecstasy pills M Baggott, B Heifets, RT Jones, J Mendelson, E Sferios, J Zehnder Jama 284 (17), 2190-2190, 2000 | 159 | 2000 |
| Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4: 1 ratio for treatment? J Mendelson, RT Jones Drug and alcohol dependence 70 (2), S29-S37, 2003 | 156 | 2003 |
| Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers J Mendelson, RT Jones, S Welm, M Baggott, I Fernandez, AK Melby, ... Psychopharmacology 141, 37-46, 1999 | 133 | 1999 |
| Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality DS Harris, JE Mendelson, ET Lin, RA Upton, RT Jones Clinical pharmacokinetics 43, 329-340, 2004 | 116 | 2004 |
| A randomized, placebo‐controlled trial of sustained‐release dextroamphetamine for treatment of methamphetamine addiction GP Galloway, R Buscemi, JR Coyle, K Flower, JD Siegrist, LA Fiske, ... Clinical Pharmacology & Therapeutics 89 (2), 276-282, 2011 | 107 | 2011 |
| Use patterns and self-reported effects of Salvia divinorum: an internet-based survey MJ Baggott, E Erowid, GP Galloway, J Mendelson Drug and alcohol dependence 111 (3), 250-256, 2010 | 103 | 2010 |
| Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine. J Mendelson, K Flower, MJ Pletcher, GP Galloway Experimental and clinical psychopharmacology 16 (5), 435, 2008 | 93 | 2008 |
| Asymmetric dimethylarginine (ADMA)—a modulator of nociception in opiate tolerance and addiction? A Kielstein, D Tsikas, GP Galloway, JE Mendelson Nitric Oxide 17 (2), 55-59, 2007 | 81 | 2007 |
| Mechanisms and genetics of antipsychotic‐associated weight gain SL Balt, GP Galloway, MJ Baggott, Z Schwartz, J Mendelson Clinical Pharmacology & Therapeutics 90 (1), 179-183, 2011 | 76 | 2011 |
Matthew BaggottTactogen IncVerified email at uchicago.edu
